In contrast to previous findings where high SPINK1 expression was associated with poor prognosis in CRC, the results of Chen et al. demonstrate that high SPINK1 expression correlates with improved overall survival in stage IV KRAS wild-type CRC patients receiving cetuximab-based anti-EGFR therapy. The gene discussed is EGFR; the disease is colorectal carcinoma.